GlaxoSmithKline: Atherosclerosis trials

The registry lists 32 Atherosclerosis studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 19Phase 2 8Phase 3 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 TrialCompletedNCT01000727Phase 3Results posted
• The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy TrialCompletedNCT00799903Phase 3Results posted
• A Phase II Clinical Study of SB-480848 in Dyslipidemic PatientsCompletedNCT00734032Phase 2Results posted
• A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT ImagingCompletedNCT00633022Phase 2Results posted
• Integrated Biomarker And Imaging Study - 2CompletedNCT00268996Phase 2Results posted
• Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 DiabetesCompletedNCT00116831Phase 3Results posted
• Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02058641Phase 1
• Darapladib China PKCompletedNCT02000804Phase 1
• Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid EndarterectomyCompletedNCT01916720Phase 2
• Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy SubjectsCompletedNCT01873339Phase 1
• Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).CompletedNCT01852565Phase 1
• To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy VolunteersCompletedNCT01751074Phase 1
• A Study to Assess the Effect of SB 659032 on Platelet FunctionCompletedNCT01750827Phase 1
• SB-659032 Platelet Aggregation StudyCompletedNCT01745458Phase 1
• A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal ImpairmentCompletedNCT01711723Phase 1
• SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)CompletedNCT01636271
• Study to Evaluate Darapladib in Moderately Hepatically Impaired SubjectsCompletedNCT01154114Phase 1
• A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848CompletedNCT00743860Phase 1
• A Study With Darapladib to Collect Tolerability InformationCompletedNCT00704431Phase 1
• An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 WeeksCompletedNCT00695305Phase 2
• Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-CompletedNCT00622830Phase 1
• A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese MenCompletedNCT00551317Phase 1
• A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy MenCompletedNCT00549653Phase 1
• A Study to Examine the Effect of Particle Size on Bioequivalence and BioavailabilityCompletedNCT00517543Phase 1
• Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia.CompletedNCT00474864Phase 2
• Comparison Of Two Tablet Formulations Of SB-568859CompletedNCT00470145Phase 1
• Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The HeartCompletedNCT00411073Phase 1
• Effect Of Rilapladib (SB-659032) On Platelet AggregationCompletedNCT00387257Phase 1
• Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance ImagingCompletedNCT00368589
• A Study To Determine The Effect Of SB-480848 On AsthmaCompletedNCT00368576Phase 1
• A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous InterventionCompletedNCT00291902Phase 2
• SB-480848 In Subjects With Coronary Heart DiseaseCompletedNCT00269048Phase 2